JP2016116527A5 - - Google Patents

Download PDF

Info

Publication number
JP2016116527A5
JP2016116527A5 JP2016023490A JP2016023490A JP2016116527A5 JP 2016116527 A5 JP2016116527 A5 JP 2016116527A5 JP 2016023490 A JP2016023490 A JP 2016023490A JP 2016023490 A JP2016023490 A JP 2016023490A JP 2016116527 A5 JP2016116527 A5 JP 2016116527A5
Authority
JP
Japan
Prior art keywords
antibody
treatment
mammalian
fibrosis
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016023490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016116527A (ja
JP6223483B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016116527A publication Critical patent/JP2016116527A/ja
Publication of JP2016116527A5 publication Critical patent/JP2016116527A5/ja
Application granted granted Critical
Publication of JP6223483B2 publication Critical patent/JP6223483B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016023490A 2010-07-15 2016-02-10 カドヘリン−11のec1ドメインを標的とするヒト化抗体ならびに関連組成物および方法 Expired - Fee Related JP6223483B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36469810P 2010-07-15 2010-07-15
US61/364,698 2010-07-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013519849A Division JP5886283B2 (ja) 2010-07-15 2011-07-15 カドヘリン−11のec1ドメインを標的とするヒト化抗体ならびに関連組成物および方法

Publications (3)

Publication Number Publication Date
JP2016116527A JP2016116527A (ja) 2016-06-30
JP2016116527A5 true JP2016116527A5 (https=) 2016-09-08
JP6223483B2 JP6223483B2 (ja) 2017-11-01

Family

ID=44630044

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013519849A Expired - Fee Related JP5886283B2 (ja) 2010-07-15 2011-07-15 カドヘリン−11のec1ドメインを標的とするヒト化抗体ならびに関連組成物および方法
JP2016023490A Expired - Fee Related JP6223483B2 (ja) 2010-07-15 2016-02-10 カドヘリン−11のec1ドメインを標的とするヒト化抗体ならびに関連組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013519849A Expired - Fee Related JP5886283B2 (ja) 2010-07-15 2011-07-15 カドヘリン−11のec1ドメインを標的とするヒト化抗体ならびに関連組成物および方法

Country Status (21)

Country Link
US (2) US8940300B2 (https=)
EP (2) EP2593128B1 (https=)
JP (2) JP5886283B2 (https=)
KR (1) KR101695056B1 (https=)
CN (2) CN103153331B (https=)
AU (1) AU2011279044B2 (https=)
BR (1) BR112013001062A2 (https=)
CA (1) CA2805112A1 (https=)
DK (1) DK2593128T3 (https=)
ES (1) ES2665317T3 (https=)
HR (1) HRP20180563T1 (https=)
HU (1) HUE038000T2 (https=)
IL (2) IL224186A (https=)
LT (1) LT2593128T (https=)
MX (1) MX343376B (https=)
NO (1) NO2593128T3 (https=)
PT (1) PT2593128T (https=)
RS (1) RS57215B1 (https=)
SG (1) SG187097A1 (https=)
SI (1) SI2593128T1 (https=)
WO (1) WO2012009631A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5511684B2 (ja) 2008-01-11 2014-06-04 アドヘロン セラピューティクス,インコーポレイテッド 炎症性関節障害を治療するためのカドヘリン−11eclドメインアンタゴニスト
US8940300B2 (en) 2010-07-15 2015-01-27 Adheron Therapeutics, Inc. Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
US8609820B2 (en) 2011-10-28 2013-12-17 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
NZ629296A (en) 2012-01-27 2016-06-24 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
EP2830659A1 (en) * 2012-03-27 2015-02-04 Novartis AG Treatment of fibrosis
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2970488A2 (en) * 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25 antibodies and their uses
MX2015012563A (es) * 2013-03-15 2016-10-26 Abbvie Biotechnology Ltd Anticuerpos anti-cd25 y sus usos.
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2016100301A1 (en) * 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
CN113817060B (zh) * 2016-01-09 2024-03-08 嘉立医疗科技(广州)有限公司 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
HRP20260034T1 (hr) * 2018-08-01 2026-02-27 Imcheck Therapeutics Anti-btn3a antitijela i njihova upotreba u liječenju raka ili infektivnih poremećaja
CN113072633B (zh) * 2021-04-21 2022-11-15 湖北医药学院 Cdh11截短型变体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co TRYPTOPHANE GENERATING MICROORGANISM.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
ES2120949T4 (es) 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
JP3560252B2 (ja) * 1992-08-28 2004-09-02 アベンティス ファーマ株式会社 骨関連カドヘリン様タンパク質およびその製造法
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
WO1999057149A2 (en) * 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
US6638911B1 (en) 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
ATE479441T1 (de) 1999-09-03 2010-09-15 Brigham & Womens Hospital Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien
US6787136B1 (en) 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
US20040110755A1 (en) 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
AU2003298475A1 (en) 2002-11-14 2004-06-18 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
EP1853255A4 (en) 2005-02-22 2009-07-08 Gemin X Pharmaceuticals Canada METHOD FOR TREATING ARTHRITIS WITH TRIHETEROCYCLIC COMPOUNDS
JP5511684B2 (ja) * 2008-01-11 2014-06-04 アドヘロン セラピューティクス,インコーポレイテッド 炎症性関節障害を治療するためのカドヘリン−11eclドメインアンタゴニスト
US20100322926A1 (en) 2008-02-11 2010-12-23 Novartis Ag Methods of using cadherin 11 (cdh11) antagonists
US8940300B2 (en) 2010-07-15 2015-01-27 Adheron Therapeutics, Inc. Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods

Similar Documents

Publication Publication Date Title
JP2016116527A5 (https=)
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
JP2018127467A5 (https=)
JP2018504907A5 (https=)
JP2017176174A5 (https=)
EA201791093A1 (ru) Антитела к cd47, способы и применение
AU2018256498A1 (en) Antibodies to amyloid beta
JP2014205674A5 (https=)
MX2018015584A (es) Anticuerpos anti-pd-l1 y usos de los mismos.
EP4276114A3 (en) Cd20 binding single domain antibodies
JP2016502515A5 (https=)
JP2014534239A5 (https=)
JP2014502955A5 (https=)
PE20150002A1 (es) Anticuerpos anti-fcrn
JP2014509837A5 (https=)
JP2016515522A5 (https=)
EA201890315A1 (ru) Молекулы антител, связывающие cd22
JP2014503189A5 (https=)
JP2021504430A5 (https=)
MX395257B (es) Anticuerpos para cd40.
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
JP2014237714A5 (https=)
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion